Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Elke Jäger(Krankenhaus Nordwest), Stephan Probst(Klinikum Bielefeld), Akin Atmaca(Heidelberg University), G. Wilhelm(Heidelberg University), Johannes Grossmann(Heidelberg University), Jan Stoehlmacher(University of Southern California), Ralf‐Dieter Hofheinz(University of Mannheim), Susanna Hegewisch‐Becker, Volker Rethwisch(Klinikum Dortmund), Gunter Schuch(Praxis für Hämatologie und Onkologie), Harald Schmalenberg(Heidelberg University), Carsten Bokemeyer(Universität Hamburg), J. T. Hartmann(Heidelberg University), Alexander Knuth(National Center for Cancer Care and Research), Hans Günter Derigs(Heidelberg University), Stephan Hollerbach(Heidelberg University), Claudia Pauligk(Goethe University Frankfurt), G. Seipelt, Nils Homann(Fraunhofer Project Centre Wolfsburg)
Cited by 784
Related Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k